Gastroparesis Treatment in Dallas, TX

What Is Gastroparesis?

Gastroparesis is a chronic motility disorder of the stomach in which the stomach takes too long to empty its contents into the small intestine, despite the absence of a physical obstruction. The word gastroparesis literally means "stomach paralysis," though in most cases the stomach is not completely paralyzed but rather empties significantly more slowly than normal. This delayed gastric emptying causes food to remain in the stomach for hours longer than it should, leading to a constellation of symptoms including nausea, vomiting, bloating, early satiety, and abdominal pain.

Gastroparesis affects approximately 5 million Americans, though the true prevalence is likely higher because many cases go undiagnosed or are misattributed to other conditions. The condition disproportionately affects women, who account for approximately 80 percent of diagnosed cases. While gastroparesis is not typically life-threatening, it can significantly impair quality of life, cause nutritional deficiencies, and lead to complications such as dehydration, malnutrition, bezoar formation, and poor blood sugar control in patients with diabetes.

At Texas Gut Health in Sachse, TX, Dr. Jaison John provides comprehensive evaluation and management of gastroparesis for patients throughout the Dallas-Fort Worth area. Dr. John completed his gastroenterology fellowship at UT Medical Branch, where he served as Chief Fellow, and his internal medicine residency at UT Austin Dell Medical School, where he served as Chief Resident. He holds dual board certifications from the American Board of Internal Medicine in both internal medicine and gastroenterology.

Causes of Gastroparesis

Normal gastric emptying relies on a coordinated interaction between the stomach muscles, the nervous system (particularly the vagus nerve), and specialized pacemaker cells called interstitial cells of Cajal. When any component of this system is disrupted, gastroparesis can result. The three most common categories of gastroparesis are:

Diabetic Gastroparesis

Diabetes mellitus is the most well-known and most studied cause of gastroparesis, accounting for approximately one-third of cases. Chronically elevated blood sugar levels can damage the vagus nerve (diabetic autonomic neuropathy), which controls the muscles of the stomach and coordinates gastric motility. Diabetic gastroparesis can occur in both type 1 and type 2 diabetes and tends to develop after many years of poorly controlled blood sugar. Importantly, gastroparesis and diabetes create a vicious cycle: delayed gastric emptying makes blood sugar control unpredictable, and hyperglycemia further slows gastric emptying.

Post-Surgical Gastroparesis

Gastroparesis can develop after certain surgical procedures, particularly those involving the stomach, esophagus, or vagus nerve. Fundoplication surgery for GERD, bariatric (weight loss) surgery, and other upper abdominal operations can inadvertently damage the vagus nerve or alter the anatomy of the stomach in ways that impair normal emptying. In many cases, post-surgical gastroparesis improves over time as tissues heal and the nervous system adapts, but some patients develop persistent symptoms.

Idiopathic Gastroparesis

In approximately one-third of cases, no identifiable cause can be found, and the condition is classified as idiopathic gastroparesis. Research suggests that many of these cases may be triggered by a viral infection (sometimes called post-viral gastroparesis) that damages the nerves or interstitial cells of Cajal in the stomach wall. Some patients with idiopathic gastroparesis experience gradual improvement over months to years, while others have a more persistent course.

Other Causes

Less common causes of gastroparesis include:

• Medications — Opioid pain medications, certain antidepressants (particularly tricyclics), anticholinergics, and GLP-1 receptor agonists (such as semaglutide and tirzepatide) can slow gastric emptying.
• Neurological conditions — Parkinson's disease, multiple sclerosis, and other neurological disorders can affect the nerves controlling stomach motility.
• Connective tissue disorders — Scleroderma and amyloidosis can involve the smooth muscle of the stomach.
• Hypothyroidism — Underactive thyroid function can slow gastrointestinal motility throughout the digestive tract.
• Eating disorders — Longstanding anorexia nervosa and bulimia can impair gastric motility.

Symptoms of Gastroparesis

The symptoms of gastroparesis can range from mild to severe and often fluctuate over time, with periods of relative well-being alternating with symptom flares. The cardinal symptoms include:

• Nausea — The most common symptom, reported by approximately 90 percent of patients. Nausea may be constant or occur primarily after eating and can be the most debilitating aspect of the condition.
• Vomiting — Vomiting of partially digested food, sometimes hours after eating, is characteristic of gastroparesis. In severe cases, patients may vomit food eaten the previous day. Vomiting provides temporary symptom relief for some patients.
• Early satiety — Feeling uncomfortably full after eating only a small amount of food. This occurs because the stomach retains food from previous meals, leaving less room for new food.
• Postprandial fullness — An exaggerated, uncomfortable sense of fullness that persists long after a meal.
• Abdominal bloating and distension — A feeling of swelling or tightness in the upper abdomen, often visible as physical distension.
• Abdominal pain — Upper abdominal pain or discomfort is reported by approximately 50 to 90 percent of gastroparesis patients. The pain is typically in the epigastric (upper central) or left upper quadrant area.
• Weight loss and malnutrition — Chronic nausea, vomiting, and reduced food intake can lead to significant weight loss and nutritional deficiencies.
• Gastroesophageal reflux — Delayed gastric emptying increases the likelihood of acid and food refluxing into the esophagus, causing heartburn and other GERD symptoms.
• Erratic blood sugar levels — In diabetic patients, unpredictable gastric emptying makes it difficult to match insulin dosing to food absorption, causing episodes of both hyperglycemia and hypoglycemia.

Diagnosis

Diagnosing gastroparesis requires demonstrating delayed gastric emptying in the absence of a mechanical obstruction. The diagnostic evaluation typically includes:

Upper Endoscopy (EGD)

An upper endoscopy is usually one of the first tests performed to rule out a physical obstruction in the stomach or duodenum, such as a peptic ulcer, pyloric stenosis, or tumor, that could mimic gastroparesis symptoms. During the procedure, Dr. John examines the esophagus, stomach, and upper small intestine and may take biopsies to evaluate for conditions such as celiac disease or eosinophilic gastroenteritis.

Gastric Emptying Scintigraphy

The gastric emptying study (GES) is the gold standard diagnostic test for gastroparesis. During this test, the patient eats a standardized meal (typically eggs and toast) that contains a small amount of a safe radioactive tracer. Imaging is then performed at 1, 2, 3, and 4 hours after the meal to measure the percentage of food remaining in the stomach at each time point. According to the American College of Gastroenterology (ACG), gastroparesis is defined as greater than 10 percent gastric retention at 4 hours.

Important considerations for accurate testing include:

• Prokinetic medications and opioids should be stopped at least 48 to 72 hours before the test
• Blood sugar should be well controlled at the time of the study (ideally below 275 mg/dL), as hyperglycemia itself can delay gastric emptying
• The full 4-hour study should be completed, as shorter protocols can miss delayed emptying in some patients

Motility Testing

In some cases, additional motility testing may be recommended to evaluate the function of the esophagus and other parts of the gastrointestinal tract, particularly if symptoms suggest a more widespread motility disorder. Wireless motility capsule (SmartPill) testing can measure gastric emptying, small bowel transit, and colonic transit in a single study, providing a comprehensive assessment of gastrointestinal motility.

Treatment and Management

Gastroparesis management is multimodal and tailored to the severity of symptoms, the underlying cause, and each patient's nutritional status. The goals of treatment are to improve gastric emptying, control symptoms, correct nutritional deficiencies, and improve quality of life.

Dietary Modifications

Dietary changes are the foundation of gastroparesis management and should be implemented in all patients. The ACG recommends the following dietary strategies:

• Eat smaller, more frequent meals — Five to six small meals per day instead of three large ones reduces the volume of food in the stomach at any given time, allowing more efficient emptying.
• Low-fat diet — Fat slows gastric emptying, so limiting fat intake can improve symptoms. Emphasize lean proteins such as chicken, fish, and eggs.
• Low-fiber diet — While fiber is generally beneficial for digestive health, insoluble fiber (found in raw vegetables, skins, seeds, and nuts) can be difficult to empty from a poorly functioning stomach and may contribute to bezoar formation. During flares, a low-residue or liquid diet may be necessary.
• Blended or pureed foods — Liquids and pureed foods empty from the stomach faster than solid foods. Smoothies, soups, and pureed meals can be well-tolerated during symptom flares.
• Chew food thoroughly — Thorough chewing breaks food into smaller particles that are easier for the stomach to process.
• Stay upright after meals — Remaining upright for at least 1 to 2 hours after eating and taking a gentle walk can facilitate gastric emptying by harnessing gravity and mild physical activity.
• Stay well hydrated — Adequate fluid intake is important, particularly for patients who vomit frequently. Electrolyte-containing beverages may be helpful.

Glycemic Control

For patients with diabetic gastroparesis, optimizing blood sugar control is a critical and often underemphasized component of treatment. Hyperglycemia directly inhibits gastric motility, and improved glucose control has been shown to improve gastric emptying rates. Close collaboration between the gastroenterologist and endocrinologist or primary care physician is essential.

Medications

When dietary modifications alone are insufficient, pharmacologic therapy may be added:

• Metoclopramide (Reglan) — The only FDA-approved medication for gastroparesis. Metoclopramide is a prokinetic agent that stimulates stomach contractions and an antiemetic that reduces nausea. Due to the risk of tardive dyskinesia (involuntary muscle movements) with long-term use, the FDA recommends limiting treatment to 12 weeks when possible, though some patients require longer courses under careful supervision.
• Domperidone — A prokinetic agent similar to metoclopramide but with a lower risk of central nervous system side effects. Domperidone is not FDA-approved but can be obtained through a special FDA compassionate use program for patients who have failed other therapies.
• Antiemetics — Ondansetron (Zofran), promethazine (Phenergan), and prochlorperazine (Compazine) can help manage nausea and vomiting but do not improve gastric emptying.
• Neuromodulators — Low-dose tricyclic antidepressants (such as nortriptyline or amitriptyline) and mirtazapine may reduce nausea, improve appetite, and modulate visceral pain perception in gastroparesis patients.
• Erythromycin — A macrolide antibiotic that acts as a motilin receptor agonist, stimulating gastric contractions. Its prokinetic effect tends to diminish over time (tachyphylaxis), so it is generally used short-term or intermittently.

Endoscopic and Procedural Interventions

For patients with moderate to severe gastroparesis who do not respond adequately to dietary modifications and medications, advanced interventions may be considered:

• Pyloric botulinum toxin injection — Botox injection into the pylorus (the valve between the stomach and small intestine) during upper endoscopy can temporarily relax the pyloric sphincter. While initial studies showed mixed results, it may benefit selected patients with documented pyloric dysfunction.
• Gastric per-oral endoscopic myotomy (G-POEM) — An emerging endoscopic procedure in which the pyloric muscle is cut from the inside of the stomach using techniques adapted from POEM for achalasia. Early studies have shown promising results, with significant symptom improvement in 70 to 80 percent of patients. The ACG recognizes G-POEM as a potential option for refractory gastroparesis.
• Gastric electrical stimulation (GES) — A surgically implanted device (Enterra) that delivers mild electrical pulses to the stomach. FDA-approved under a humanitarian device exemption for patients with chronic, refractory gastroparesis, it may reduce nausea and vomiting in selected patients, though it does not consistently improve gastric emptying.

Nutritional Support

Patients with severe gastroparesis who cannot maintain adequate nutrition through oral intake may require supplemental nutrition:

• Jejunal feeding tube — A feeding tube placed into the jejunum (the second part of the small intestine), bypassing the stomach entirely. This allows direct delivery of nutrition to the functioning portion of the intestine.
• Parenteral nutrition (TPN) — Intravenous nutrition reserved for the most severe cases where enteral feeding is not tolerated or feasible.

Complications of Gastroparesis

When inadequately managed, gastroparesis can lead to several complications:

• Malnutrition and weight loss — Chronic nausea, vomiting, and reduced oral intake can result in calorie and micronutrient deficiencies.
• Dehydration and electrolyte imbalances — Frequent vomiting can deplete fluids and essential electrolytes such as potassium and magnesium.
• Bezoar formation — Undigested food can accumulate in the stomach and form a solid mass called a bezoar, which can cause further obstruction, ulceration, and worsening symptoms. Bezoars may need to be removed endoscopically.
• Erratic blood sugar control — In diabetic patients, unpredictable food absorption makes glycemic management extremely challenging and increases the risk of dangerous hypoglycemia and hyperglycemia.
• Reduced quality of life — The chronic, unpredictable nature of gastroparesis symptoms can significantly impact social functioning, work productivity, and emotional well-being. Anxiety and depression are common among gastroparesis patients.

Frequently Asked Questions